Using the CNBC RQ 50 measure for R&D productivity, we've identified an elite group of companies that merit election to an R&D hall of fame.» Read More
Take a look at some of Friday’s morning movers:
Take a look at some of Tuesday’s morning movers:
Carl Icahn is no stranger to conflict and controversy. But this time, his rhetoric isn’t only scathing, it’s also rather serious.
Investor Carl Icahn updates "Fast Money" on what he wants to see happen to a company he calls a "very undervalued asset."
Billionaire investor Carl Icahn questioned the timing of certain stock sales by Forest Laboratories' CEO Howard Soloman today, and discusses his concerns over its corporate governance.
Despite the flurry of debate surrounding ObamaCare, which the U.S. Supreme Court is set to rule on later this week, two managing directors emphasized the new products that will be emerging from pharmaceutical companies’ pipelines soon.
Take a look at some of Tuesday's midday movers:
Take a look at some of Monday's midday movers:
Stocks closed lower Thursday with all three major averages logging their worst May since 2010, driven by mounting concerns over the euro zone debt crisis in addition to worries over a slowing U.S. economy.
U.S. stock index futures pared their early Thursday following a pair of weak jobs data and after news the economy grew at a slower pace than expected.
Take a look at some of Thursday’s morning movers:
Take a look at some of Wednesday's midday movers:
Yet another Vivus takeover rumor circulating through the market Tuesday got me thinking: When do most biotech and drug takeovers happen?
Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!
Carl Icahn tells us that the company he’s most focused on right is Forest Labs. “That’s the company where activism is needed,” he says.
Forest Laboratories said it won backing from proxy advisory firm ISS for all 10 of its board nominees in a proxy battle with billionaire investor Carl Icahn.
What follows is a look at stocks in the S&P 1,500 displaying unusual volume in Monday's trading session.
In the next 14 months, patents for the top 20 drugs in the U.S. are set to expire. Although makers of such top-selling drugs, such as Lipitor and Plavix, will no longer have a monopoly on these drug formulas, pharmaceutical stocks will be able to weather the loss of these patents, said two health-care analysts.
Analysts from health care equity research firm Leerink Swaan expect major pharmaceutical companies to beat their second-quarter estimates.
Here's why you should keep a close eye on these six stocks.